CZL-149

Overview

CZL-149 is an orally active dual BET and p300/CBP bromodomains inhibitor with IC 50 s of 13 nM and 10.5 nM for BED4 BD1 and p300, respectively. CZL-149 reduces c-Myc and H3K27Ac levels. CZL-149 has good drug-like properties and metabolic characteristics, as well as good safety. CZL-149 can be used for the study of multiple myeloma.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Multiple Myeloma | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Epigenetic Reader Domain | Products > Signaling Pathways > Histone Acetyltransferase

Product Information

• Catalog No.: HY-183992
• CAS No.: 3094772-96-7
• Molecular Formula: C23H23F3N4O3
• Molecular Weight: 460.45
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source